SAN DIEGO -- A fixed-duration oral combination significantly reduced the risk of disease progression or death compared with ...
A novel, fixed-duration drug combination—consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 ...
The AMPLIFY Phase III trial demonstrates that acalabrutinib plus venetoclax significantly improves progression-free survival ...
Positive results from the AMPLIFY Phase III trial have shown that adding AstraZeneca’s Calquence (acalabrutinib) to ...
Current treatments for patients with relapsed or refractory chronic lymphocytic leukemia have shown better outcomes than ...
Researchers at Dana-Farber Cancer Institute are presenting a promising advance in the treatment of chronic lymphocytic ...
Meaningful change thresholds for the EORTC Quality of Life Questionnaire in chronic lymphocytic leukemia (CLL) or small ...
Susan L. Slager, PhD, discusses the background of her research on inherited germline genetics for risk of chronic lymphocytic ...
Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...
This multiyear follow-up of more than 3300 patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who ...
Grandad William Bennett, 69, was diagnosed with chronic lymphocytic leukaemia (CLL) 12 years ago, a type of blood cancer ...
Researchers found no significant differences in the risk of overall adverse events (AEs), but there were significant differences in grade 3 or higher AEs, serious AEs, treatment discontinuations due ...